XML 39 R15.htm IDEA: XBRL DOCUMENT
v3.22.4

Intangible Assets and Goodwill | 12 Months Ended
--- | ---
Jan. 01, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets and Goodwill | Intangible Assets and Goodwill At the end of fiscal years 2022 and 2021, the gross and net amounts of intangible assets were:
(Dollars in Millions) |  | 2022 |  | 2021
Intangible assets with definite lives: |  |  |  |
Patents and trademarks — gross |  | $ | 44,012 |  |  | 38,572 |
Less accumulated amortization |  | (22,266) |  |  | (20,088) |
Patents and trademarks — net(1) |  | $ | 21,746 |  |  | 18,484 |
Customer relationships and other intangibles — gross |  | $ | 22,987 |  |  | 23,011 |
Less accumulated amortization |  | (12,901) |  |  | (11,925) |
Customer relationships and other intangibles — net(2) |  | $ | 10,086 |  |  | 11,086 |
Intangible assets with indefinite lives: |  |  |  |
Trademarks |  | $ | 6,807 |  |  | 6,985 |
Purchased in-process research and development(3) |  | 9,686 |  |  | 9,837 |
Total intangible assets with indefinite lives |  | $ | 16,493 |  |  | 16,822 |
Total intangible assets — net |  | $ | 48,325 |  |  | 46,392 |
(1)The change was primarily related to the intangible assets acquired with the acquisition of Abiomed, Inc. which was partially offset by amortization expense of previously existing intangible assets and the result of currency translation effects. (2)The majority is comprised of customer relationships (3)The reduction was primarily related to an intangible asset impairment charge of approximately $0.8 billion recorded in the fiscal year 2022 related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS. An additional reduction of $0.7 billion was driven by Monarch assets that reached commercialization and are now classified as having definite lives. This was partially offset by approximately $1.1 billion of IPR&D acquired with Abiomed, Inc. Goodwill as of January 1, 2023 and January 2, 2022, as allocated by segment of business, was as follows:
(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total
Goodwill at January 3, 2021 |  | $ | 10,336 |  |  | 11,009 |  |  | 15,048 |  |  | 36,393 |
Goodwill, related to acquisitions |  | — |  |  | — |  |  | — |  |  | — |
Goodwill, related to divestitures |  | (9) |  |  | — |  |  | — |  |  | (9) |
Currency translation/other |  | (517) |  |  | (429) |  |  | (192) |  |  | (1,138) |
Goodwill at January 2, 2022 |  | $ | 9,810 |  |  | 10,580 |  |  | 14,856 |  |  | 35,246 |
Goodwill, related to acquisitions |  | — |  |  | — |  |  | 11,056 |  |  | 11,056 |
Goodwill, related to divestitures |  | — |  |  | — |  |  | — |  |  | — |
Currency translation/other |  | (626) |  |  | (396) |  |  | (49) |  |  | (1,071) |
Goodwill at January 1, 2023 |  | $ | 9,184 |  |  | 10,184 |  |  | 25,863 |  |  | 45,231 |
The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in Cost of products sold was $4.3 billion, $4.7 billion and $4.7 billion before tax, for the fiscal years ended January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions) |  |  |  |  |  |
2023 |  | 2024 |  | 2025 |  | 2026 |  | 2027
$4,600 |  | 4,400 |  | 3,600 |  | 3,000 |  | 2,400
See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration